It’s vital that we continue to drive the development of novel therapies, so that myeloma patients can benefit from the most important advances in cancer treatment. We do this by investing directly in early-stage biopharma companies with promising technologies and conducting clinical trials that evaluate novel treatment approaches.
This is the MMRF’s venture philanthropy subsidiary. It invests in promising companies with innovative clinical assets and technologies that could be transformative for myeloma patients.
The Myeloma Investment Fund® collaborates closely with its portfolio companies to help them advance their multiple myeloma programs and improve their probability of success. This evergreen fund is supported entirely by philanthropy; all financial returns are reinvested back into the fund until there is a cure for every patient.
The Multiple Myeloma Research Consortium® (MMRC®) is a collaborative network of leading myeloma treatment centers that conduct early-stage clinical trials to evaluate novel treatment strategies for patients. This collaborative network drives ambitious clinical studies that simply could not be done by any single institution given their size and complexity. We focus our efforts on advancing innovative treatment approaches in the highest areas of unmet clinical need for patients, including relapsed/refractory, high-risk newly diagnosed, and high-risk smoldering myeloma.
MyDRUG℠ is a groundbreaking clinical trial program that is testing multiple new treatments for patients with high-risk multiple myeloma. It is evaluating treatments that are targeted against specific genomic alterations within the myeloma cells.
The scientific hypothesis for the MyDRUG℠ clinical trial came out of our CoMMpass℠ Study, which has generated the largest myeloma genomics database openly accessible to researchers across the globe.
